Rationale: Primary central nervous system lymphoma (PCNSL) is a rare disease. Studies of PCNSL in patients with rheumatic diseases are lacking. Neither clinical symptoms nor radiographic manifestation is specific to PCNSL. Therefore, it could be misdiagnosed with other diseases such as brain tumors. Chemotherapy is the primary treatment for PCNSL, while the role of surgery remains controversial.
Introduction
Primary central nervous system lymphoma (PCNSL) is a rare disease that accounts for up to 1% of non-Hodgkin lymphomas (NHL) and approximately 3% of primary brain tumors. [1] Risk increases in patients with rheumatic diseases, partially due to the use of immunosuppressant. [2] Magnetic resonance imaging (MRI) manifestation is not specific to PCNSL and mimics other brain tumors. Herein, we reported a 39-year-old woman with systemic lupus erythematosus (SLE) who developed PCNSL after years of multiple immunosuppressant treatment. The radiographic presentation of PCNSL mimicked glioma. Ethics committee of the First Affiliated Hospital of Sun Yat-sen University approved the research. Informed consent was obtained from the patient.
Case report
A 39-year-old woman was admitted because of headache and nausea for 2 weeks. She was diagnosed with SLE for 15 years and had been treated with prednisone and hydroxychloroquine (HCQ). Five years after disease onset, she had lupus nephritis. Methotrexate (MTX) and cyclosporin A (CsA) were added. One and a half years before admission, mycophenolate mofetil (MMF) 1 g twice a day was prescribed instead of MTX and CsA. Physical examination showed neck stiffness. Serum C3 level was 0.64 g/L. Titer of ANA was 1:1000 in speckled pattern. Titer of anti-dsDNA antibody was 364.61 IU/mL (normal range 0-12 IU/ mL). Anti-SSA and anti-SSB antibodies were negative. The MRI showed a massive tumor of 60 mm Â 47 mm Â 34 mm in the right frontal lobe (Fig. 1A, B) and a nodular nidus in the cortex of the right parietal lobe (Fig. 1C, D) . Lesion in the frontal lobe was diagnosed with glioma, radiographically. Lesion in the parietal lobe was considered as cerebral infarction. Considering the acute symptoms of intracranial hypertension, gross tumor resection was carried out. Intraoperative frozen section examination found coagulation necrosis as well as atypical cell infiltration. Glioblastoma was diagnosed according to the pathological finding. However, pathological examination postoperatively showed atypical lymphoid cells accumulated in perivascular site ( Fig. 2A, B) . Immunohistochemical staining for CD20 was positive (Fig. 2C) . The Ki-67 proliferation index was 50%. In situ hybridization for EBER was positive (Fig. 2D) . She was diagnosed with diffuse large B-cell lymphoma (DLBCL). MMF was discontinued before surgery. Bone marrow biopsy was normal. Positron emission tomography-computed tomography (PET-CT) performed postoperatively showed an increased uptake within the nidus located in the right parietal lobe. SUVmax value was 12.1. She received 6 cycles of chemotherapy with methotrexate, cytarabine, temozolomide and rituximab, and autologous stem cell transplantation (ASCT) subsequently. The symptom of intracranial hypertension was relieved postoperatively, and the patient remained complete remission until this article was written.
Discussion
PCNSL is well studied in patients with acquired immune deficiency syndrome (AIDS) or organ transplantation. However, it is rarely diagnosed in rheumatic diseases. Scattered cases of immunodeficiency-related PCNSL have been reported in patients with rheumatoid arthritis (RA), myasthenia gravis, and Crohn disease. [3] [4] [5] Until recently, only 8 cases of SLE accompanied with PCNSL were reported in English literature. Radiographic information was recorded in 7 patients and is summarized in Table 1 . [2] [3] [4] [5] [6] [7] [8] Among the 7 cases, 3 had multiple lesions. One lesion was infratentorial, while the others were supratentorial. MRI showed homogeneous enhancing lesions in 2 patients, and peripheral enhancing lesions in the other 5 cases. Three cases were considered as infectious diseases initially, including toxoplasmosis, nocardia, and abscess. Mass excision was performed in 2 cases. Detection of EBER was positive in 5 cases and negative in 1. [6] 67/F 30 y Intermittent prednisone treatment 1 1 cm Hypothalamus --Homogeneous hyperintensity -Tse et al [7] 28/F Not mentioned MMF for 11 y 1 3.9 cm x 6.4 cm x 4.7 cm
Left frontal lobe
Lesion discovered by CT scan had thin contrastenhancing rims and nonenhancing central areas with perifocal edema. Woolf et al [8] 54/F 21 years AZA for 9 mo Multiple Not mentioned Right temporal and parietal lobes CT scan showed homogeneously enhancing lesion.
AZA = azathioprine, CT = computed tomography, CYC = cyclophosphamide, FLAIR = fluid-attenuated inversion recovery, MMF = mycophenolate mofetil, PCNSL = primary central nervous system lymphoma, SLE = systemic lupus erythematosus, T1WI = T1-weighted image, T2WI = T2-weighted image.
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and impairment of immunosurveillance promote the development of malignancy. [6] The risk of NHL increases in patients with SLE. DLBCL is the most frequent, accounting for nearly 90% of the cases. [7] Besides, the increasing risk of lymphoma could be partially attributed to antirheumatic therapy. It is reported that the incidence of central nervous system (CNS) post-transplant lymphoproliferative disease was the highest in renal transplant patients who took MMF. [8] All the lupus patients who were reported to develop PCNSL had taken MMF. Time interval from the initial use of MMF to the onset of PCNSL varied from 1 year to 11 years. Different from previous reports, the patient in our case also took MTX and CsA. The use of azathioprine (AZA), cyclophosphamide (CYC), and MTX has been reported to increase hematological cancer risk in SLE. [9] In particular, most cases of MTX-associated lymphoma are B-cell lymphoma with extranodal involvement. [10] Therefore, the development of PCNSL in the present case could be cocktail effect of the use of multiple immunosuppressant. The causal relationship needs to be evidenced with further research.
Our report reinforced the disparity in radiographic manifestation of PCNSL in immunodeficiency patients. MRI of PCNSL in immunocompetent patients usually displays hypointensity signal in T2-weighted image (T2WI) and homogeneous postcontrast enhancement in T1WI, which is different from that of glioma. However, 5 of 7 reviewed cases and our patient showed ring-like enhancing lesions, suggesting that noncanonical manifestation of PCNSL was relatively common in patients with SLE. PCNSL in immunocompromised hosts contains blood products or necrosis, so it may present heterogeneous contrast enhancement. It is also reported that morphological differentiation between PCNSL and glioma by MRI is difficult. Lesion of PCNSL can locate supra-or infra-tentoria, involve basal ganglia or cerebral cortex, and infiltrate diffusely. [11] In our case, 2 lesions in the right hemisphere were considered as glioma and ischemic stroke before surgery, respectively. PET-CT demonstrated an increasing uptake within the lesion located in the right parietal lobe and SUVmax was moderately elevated. Taking histopathological findings into consideration, we speculate that both lesions in the right hemisphere were lymphoma-related.
Chemotherapy is the primary treatment for PCNSL. However, recent research suggested subtotal or gross resection in combination with chemotherapy may prolong progression-free survival. [12] Surgery is considered in the case of large, compressive lesion. [13] Compared with previous reports, the tumor volume in our case was the largest with remarkable midline shift, which made surgery necessary.
This report highlights the possibility of PCNSL in lupus patients treated with combined immunosuppressant. Strict vigilance must be maintained against the differential diagnosis with glioma.
